Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States

Abstract

Objective:

To evaluate breast cancer-associated healthcare cost from the payer perspective for the initial year after diagnoses of invasive breast cancer.

Background:

Breast cancer is the second most common malignancy in American women. While lifetime burden-of-care studies have reported spending between $20,000 and $100,000 per patient, previous studies have not outlined first year cost in managing this disease in recently diagnosed patients.

Methods:

This study was a retrospective, matched cohort study of privately-insured patients. Data were from a large US employers’ health claims database (January 2003–September 2008). Breast cancer cases were identified by ICD-9-CM diagnostic codes on index and confirmatory claims. A control group was identified with a ratio of 3:1, matched by demographic and health plan characteristics. Comorbidities were analyzed using the Charlson comorbidity index and AHRQ Comorbidity Software. A multivariate, log-linked, generalized linear model evaluated cost contributions of breast cancer in relation to demographic factors, comorbidities, and plan type.

Results:

The study included 35,057 cases and 105,171 matched controls (mean age 52 years). Common comorbidities included hypertension, diabetes, hypothyroidism, chronic pulmonary disease, and deficiency anemia. In the generalized linear model, the adjusted difference in total healthcare cost was $42,401 per patient within a year, with outpatient services responsible for most of this sum. Breast cancer-associated incremental annual costs per patient in inpatient, outpatient, and prescription categories were $5100, $37,231, and $1037, respectively.

Limitations:

These results may not be representative of the entire US, as data were derived from breast cancer patients with private, employer-based health insurance, and lacked covariates including race/ethnicity, education, income, and disease stage.

Conclusions:

Recently diagnosed breast cancer represents a substantial economic burden for US healthcare payers.

Keywords::

• Breast cancer
• Direct cost
• Economic burden
• Health claims
• Retrospective study

Transparency

Declaration of funding

This study was supported by Sanofi-Aventis U.S. Both authors participated in the study design, data collection, interpretation, and writing of the manuscript.

Declaration of financial/other relationships

A.Z.F. received sponsorship from Sanofi-Aventis; M.J. is an employee of Sanofi-Aventis U.S.

Acknowledgments

Editorial support was provided by David Pechar, PhD, at Phase Five Communications Inc. and funded by Sanofi-Aventis U.S.

This study was previously presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, June 4–8, 2010.